EPO published international patent application EP4130253A1 on March 25, 2026, for a T cell progenitor production method. Joint applicants are Kyoto University and Takeda Pharmaceutical Company Limited, with inventors KANEKO Shin and IRIGUCHI Shoichi. The application is classified under C12N 5/0783 (cell therapy) and A61K 35/17 (immunological preparations), covering methods for generating T cell progenitors for therapeutic use.

This is a patent application publication, not a granted patent or regulatory requirement. No immediate compliance actions are required. Companies in the cell therapy or immunotherapy space should monitor this application as it progresses through examination. The designated states cover all EU member states plus several additional European countries.